Media
Press Releases
October 15, 2024
Lupin Launches First Generic of Pred Forte® in the United States
September 18, 2024
Lupin Receives Approval from U.S. FDA for Bumetanide Injection, USP
September 4, 2024
Lupin Launches Mirabegron Extended-Release Tablets in the United States
August 29, 2024
Lupin Launches Doxorubicin Hydrochloride Liposome Injection in the United States
August 27, 2024
Lupin Receives Approval from U.S. FDA for Brimonidine Tartrate Ophthalmic Solution, 0.1%
August 14, 2024
Lupin Receives Tentative Approval from U.S. FDA for Brimonidine Tartrate Ophthalmic Solution, 0.025% (OTC)
August 5, 2024
Lupin Receives Approval from U.S. FDA for Prednisolone Acetate Ophthalmic Suspension USP
July 31, 2024
Lupin Receives Approval from U.S. FDA for Emtricitabine and Tenofovir Alafenamide Tablets
July 27, 2024
Lupin Receives Tentative Approval from U.S. FDA for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC)
Media
Rajalakshmi Azariah
Vice President & Global Head - Corporate Communications
rajalakshmiazariah@lupin.comElise Titan
Director, U.S. Communications
elisetitan@lupin.comSmart Guide
Close
CloseSearch Product